 NEW YORK, NY ACCESSWIRE August 19, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today announced that REZUROCKTM belumosudil 200 mg once daily QD tablets is now commercially available for shipment to prescribed patients in the United States. REZUROCK was approved on July 16, 2021 by the U.S. Food and Drug Administration FDA for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease cGVHD after failure of at least two prior lines of systemic therapy. 